Sean Brynjelsen

Chief Executive Officer & Director

Sean Brynjelsen is CEO of Eton Pharma and a member of the board of directors. He brings to the company more than 20 years of pharmaceutical industry experience, with particular expertise in business development and product development. Prior to joining Eton, Mr. Brynjelsen was Executive Vice President of Business Development at Sagent Pharmaceuticals, a generic injectable company that was acquired by Nichi-Iko Pharmaceuticals. Prior to Sagent, he was Senior Vice President of Global Business Development at Akorn Inc, a pharmaceutical company specializing in ophthalmic and injectable products.

Early in his career, Mr. Brynjelsen spent more than 10 years in product development focused on injectable pharmaceuticals at Baxter, Abbott, and Hospira. He has an MBA from the University of Notre Dame, and a Masters of Science in Chemistry and a Bachelor of Science in Chemistry from the University of Illinois.

Sean Brynjelsen

Chief Executive Officer & Director

Sean Brynjelsen is CEO of Eton Pharma and a member of the board of directors. He brings to the company more than 20 years of pharmaceutical industry experience, with particular expertise in business development and product development. Prior to joining Eton, Mr. Brynjelsen was Executive Vice President of Business Development at Sagent Pharmaceuticals, a generic injectable company that was acquired by Nichi-Iko Pharmaceuticals. Prior to Sagent, he was Senior Vice President of Global Business Development at Akorn Inc, a pharmaceutical company specializing in ophthalmic and injectable products.

Early in his career, Mr. Brynjelsen spent more than 10 years in product development focused on injectable pharmaceuticals at Baxter, Abbott, and Hospira. He has an MBA from the University of Notre Dame, and a Masters of Science in Chemistry and a Bachelor of Science in Chemistry from the University of Illinois.